End stage heart failure is a major challenge in the developed countries. Heart transplantation, the treatment of choice, is limited by organ supply. Left ventricular assist device (LVAD) support for the heart, is an alternative treatment. It has, however, severe complications, including stroke and pump thrombosis. Accurate diagnosis of These complications is lacking. Increased third harmonic (pump speed x 3) amplitude on pump sounds analysis has been shown to correlate with pump thrombosis. However, it’s intermittent nature and varied signal quality led to low reproducibility between studies. In this thesis we tested in vitro (paper I, III) and in vivo (paper II, III) a novel accelerometer-based detection of thromboembolism and pump thrombo...
Includes bibliographical references (pages 49-52).Currently many patients die because of the end-sta...
Introduction: Despite significant technical advancements in the design and manufacture of Left Ventr...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
ObjectiveLeft ventricular assist devices (LVADs) fail in up to 10% of patients due to the developmen...
Mechanical circulatory support technology is continually improving. However, adverse complications d...
The work in this thesis was undertaken to examine clinically significant questions at a time of evol...
Due to limited number of donor hearts and stringent eligibility criteria for heart transplant the Le...
INTRODUCTION: The HeartMate 3™ has shown lower rates of adverse events compared to previous devices ...
Background: Heart Failure is a serious condition with consequences not only for the individual patie...
Rotary left ventricular assist devices (LVADs) are commonly operated at a constant speed, attenuatin...
ObjectivesThis study sought to develop a novel approach to optimizing continuous-flow left ventricul...
textabstractBackground Despite advances in pump technology, thromboembolic events/acute pump thrombo...
Background Despite advances in pump technology, thromboembolic events/acute pump thrombosis remain p...
AbstractThe left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device...
Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are ve...
Includes bibliographical references (pages 49-52).Currently many patients die because of the end-sta...
Introduction: Despite significant technical advancements in the design and manufacture of Left Ventr...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...
ObjectiveLeft ventricular assist devices (LVADs) fail in up to 10% of patients due to the developmen...
Mechanical circulatory support technology is continually improving. However, adverse complications d...
The work in this thesis was undertaken to examine clinically significant questions at a time of evol...
Due to limited number of donor hearts and stringent eligibility criteria for heart transplant the Le...
INTRODUCTION: The HeartMate 3™ has shown lower rates of adverse events compared to previous devices ...
Background: Heart Failure is a serious condition with consequences not only for the individual patie...
Rotary left ventricular assist devices (LVADs) are commonly operated at a constant speed, attenuatin...
ObjectivesThis study sought to develop a novel approach to optimizing continuous-flow left ventricul...
textabstractBackground Despite advances in pump technology, thromboembolic events/acute pump thrombo...
Background Despite advances in pump technology, thromboembolic events/acute pump thrombosis remain p...
AbstractThe left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device...
Mechanical circulatory support (MCS) devices, such as left ventricular assist devices (LVADs) are ve...
Includes bibliographical references (pages 49-52).Currently many patients die because of the end-sta...
Introduction: Despite significant technical advancements in the design and manufacture of Left Ventr...
Heart failure is a global and growing problem that affects 1-2% of people. For patients with end-sta...